The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics

Purpose. To evaluate the associations between metformin, insulin, statins, and levothyroxine and breast cancer characteristics and outcome. Methods. Retrospective chart review of patients treated in our institute for early estrogen receptor (ER) positive, human epidermal growth factor receptor 2 neg...

Full description

Saved in:
Bibliographic Details
Main Authors: Hadar Goldvaser, Shulamith Rizel, Daniel Hendler, Victoria Neiman, Daniel Shepshelovich, Tzippy Shochat, Aaron Sulkes, Baruch Brenner, Rinat Yerushalmi
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2016/4658469
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849414588435529728
author Hadar Goldvaser
Shulamith Rizel
Daniel Hendler
Victoria Neiman
Daniel Shepshelovich
Tzippy Shochat
Aaron Sulkes
Baruch Brenner
Rinat Yerushalmi
author_facet Hadar Goldvaser
Shulamith Rizel
Daniel Hendler
Victoria Neiman
Daniel Shepshelovich
Tzippy Shochat
Aaron Sulkes
Baruch Brenner
Rinat Yerushalmi
author_sort Hadar Goldvaser
collection DOAJ
description Purpose. To evaluate the associations between metformin, insulin, statins, and levothyroxine and breast cancer characteristics and outcome. Methods. Retrospective chart review of patients treated in our institute for early estrogen receptor (ER) positive, human epidermal growth factor receptor 2 negative breast cancer, whose tumors were sent to Oncotype DX (ODX) analysis. Patients were grouped according to medications usage during the time of breast cancer diagnosis. Each group was compared to the rest of the study population. Results. The study cohort included 671 patients. Sixty (9.1%) patients were treated with metformin, 9 (1.4%) with insulin, 208 (31.7%) with statins, and 62 (9.4%) with levothyroxine. Patients treated with metformin had more intense ER stain (p=0.032) and a lower ODX recurrence score (RS) (p=0.035). Diagnosis of diabetes mellitus was also associated with lower ODX RS (p=0.014). Insulin usage was associated with a higher rate of angiolymphatic invasion (p=0.041), but lower Ki67% (p=0.017). Levothyroxine usage was associated with different histological subtype distribution (p=0.02). Extended levothyroxine usage was associated with lower ODX RS (p=0.005). Statin usage had no impact on tumor characteristics. Outcome was comparable in the studied subgroups. Conclusions. Common medications for metabolic disorders might be associated with breast cancer characteristics.
format Article
id doaj-art-6c1bb93aef584d3cb6e9008b9026dfd9
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-6c1bb93aef584d3cb6e9008b9026dfd92025-08-20T03:33:46ZengWileyInternational Journal of Endocrinology1687-83371687-83452016-01-01201610.1155/2016/46584694658469The Association between Treatment for Metabolic Disorders and Breast Cancer CharacteristicsHadar Goldvaser0Shulamith Rizel1Daniel Hendler2Victoria Neiman3Daniel Shepshelovich4Tzippy Shochat5Aaron Sulkes6Baruch Brenner7Rinat Yerushalmi8Institute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St., Petah Tikva, IsraelInstitute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St., Petah Tikva, IsraelInstitute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St., Petah Tikva, IsraelInstitute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St., Petah Tikva, IsraelSackler Faculty of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv, IsraelStatistical Consulting Unit, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St., Petah Tikva, IsraelInstitute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St., Petah Tikva, IsraelInstitute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St., Petah Tikva, IsraelInstitute of Oncology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St., Petah Tikva, IsraelPurpose. To evaluate the associations between metformin, insulin, statins, and levothyroxine and breast cancer characteristics and outcome. Methods. Retrospective chart review of patients treated in our institute for early estrogen receptor (ER) positive, human epidermal growth factor receptor 2 negative breast cancer, whose tumors were sent to Oncotype DX (ODX) analysis. Patients were grouped according to medications usage during the time of breast cancer diagnosis. Each group was compared to the rest of the study population. Results. The study cohort included 671 patients. Sixty (9.1%) patients were treated with metformin, 9 (1.4%) with insulin, 208 (31.7%) with statins, and 62 (9.4%) with levothyroxine. Patients treated with metformin had more intense ER stain (p=0.032) and a lower ODX recurrence score (RS) (p=0.035). Diagnosis of diabetes mellitus was also associated with lower ODX RS (p=0.014). Insulin usage was associated with a higher rate of angiolymphatic invasion (p=0.041), but lower Ki67% (p=0.017). Levothyroxine usage was associated with different histological subtype distribution (p=0.02). Extended levothyroxine usage was associated with lower ODX RS (p=0.005). Statin usage had no impact on tumor characteristics. Outcome was comparable in the studied subgroups. Conclusions. Common medications for metabolic disorders might be associated with breast cancer characteristics.http://dx.doi.org/10.1155/2016/4658469
spellingShingle Hadar Goldvaser
Shulamith Rizel
Daniel Hendler
Victoria Neiman
Daniel Shepshelovich
Tzippy Shochat
Aaron Sulkes
Baruch Brenner
Rinat Yerushalmi
The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics
International Journal of Endocrinology
title The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics
title_full The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics
title_fullStr The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics
title_full_unstemmed The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics
title_short The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics
title_sort association between treatment for metabolic disorders and breast cancer characteristics
url http://dx.doi.org/10.1155/2016/4658469
work_keys_str_mv AT hadargoldvaser theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT shulamithrizel theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT danielhendler theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT victorianeiman theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT danielshepshelovich theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT tzippyshochat theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT aaronsulkes theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT baruchbrenner theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT rinatyerushalmi theassociationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT hadargoldvaser associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT shulamithrizel associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT danielhendler associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT victorianeiman associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT danielshepshelovich associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT tzippyshochat associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT aaronsulkes associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT baruchbrenner associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics
AT rinatyerushalmi associationbetweentreatmentformetabolicdisordersandbreastcancercharacteristics